Results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs), were reported by University of Colorado Cancer Center researchers at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials ...Sunday, 1 June 2014
Results from the Phase I Trial of OMP-54F28 Reported
Results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs), were reported by University of Colorado Cancer Center researchers at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment